Animal data and early development literature should not be presented as proof of human weight-loss efficacy.
AOD-9604 was designed from the lipolytic region of human growth hormone. Preclinical work reported effects on adipose metabolism, but clinical efficacy for obesity has not been established to the standard of approved anti-obesity drugs.
Metabolic / lipolysis. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
Animal data and early development literature should not be presented as proof of human weight-loss efficacy.
AOD-9604 was designed from the lipolytic region of human growth hormone. Preclinical work reported effects on adipose metabolism, but clinical efficacy for obesity has not been established to the standard of approved anti-obesity drugs.
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.